Funding will propel Leyden Labs' non-vaccine intranasal antibody programs to safeguard people from respiratory viruses.

Round led by ClavystBio and Polaris Partners with strong participation from Qiming Venture Partners and continued backing from existing investors including GV (Google Ventures) and Casdin Capital.

LEIDEN, the Netherlands, Jan. 9, 2025 (GLOBE NEWSWIRE) - Leyden Laboratories B.V. today announced it has raised $70M in funding to advance its Mucosal Protection Platform.

"This strong support from investors validates our approach to providing broad, universal protection against current and future viral outbreaks," said Koenraad Wiedhaup, co-founder and chief executive officer of Leyden Labs.

"We are pleased to partner with Leyden Labs to advance the mission of protecting the world from the burden of known and new respiratory viruses," said Khoo Shih, chief executive officer of ClavystBio.

In addition to this financing, the Company announces the acquisition of CoV Biotechnology Pte. Ltd., a Singapore-based biotech company with assets developed by Linfa Wang, a professor at Duke-NUS Medical School.

About Leyden Laboratories B.V.
To learn more, visit www.leydenlabs.com.

Investor Contact: Elizabeth Goodwin, +1 781-460-1784, investors@leydenlabs.com
Media Contact: Megan Prock McGrath, CTD Comms, LLC, +1 978-800-7468, media@leydenlabs.com